Details of the Drug

General Information of Drug (ID: DMTG2O0)

Drug Name
Anrukinzumab
Synonyms Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Ulcerative colitis DD71 Phase 2 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
OU46IGC49F
DrugBank ID
DB12294
TTD ID
D03ING
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health.
2 Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.